Translating genetic and functional data into clinical practice: a series of 223 families with myotonia

Karen Suetterlin,1,2 Emma Matthews,1,3 Richa Sud,4 Samuel McCall,4 Doreen Fialho,1,5 James Burge,1,5 Dipa Jayaseelan,1 Andrea Haworth,4 Mary G. Sweeney,4 Dimitri M. Kullmann,6 Stephanie Schorge,6,7 Michael G Hanna1 and Roope Männikkö1

Abstract

High throughput DNA sequencing is increasingly employed to diagnose single gene neurological and neuromuscular disorders. Large volumes of data present new challenges in data interpretation and its useful translation into clinical and genetic counselling for families. Even when a plausible gene is identified with confidence, interpretation of the clinical significance and inheritance pattern of variants can be challenging. We report our approach to evaluating variants in the skeletal muscle chloride channel ClC-1 identified in 223 probands with myotonia congenita (MC) as an example of these challenges. Sequencing of CLCN1, the gene that encodes CLC-1, is central to the diagnosis of MC. However, interpreting the pathogenicity and inheritance pattern of novel variants is notoriously difficult as both dominant and recessive mutations are reported throughout the channel sequence, ClC-1 structure-function is poorly understood and significant intra- and interfamilial variability in phenotype is reported.

Heterologous expression systems to study functional consequences of CIC-1 variants are widely reported to aid the assessment of pathogenicity and inheritance pattern. However, heterogeneity of reported analyses does not allow for the systematic correlation of available functional and genetic data. We report the systematic evaluation of 95 CIC-1 variants in 223 probands, the largest reported patient cohort, in which we apply standardised functional analyses and correlate this with clinical assessment and inheritance pattern. Such correlation is
important to determine if functional data improves the accuracy of variant interpretation and likely mode of inheritance.

Our data provide an evidence-based approach that functional characterisation of CIC-1 variants improves clinical interpretation of their pathogenicity and inheritance pattern and serve as reference for 34 previously unreported and 28 previously uncharacterised CLCN1 variants. In addition, we identify novel pathogenic mechanisms and find that variants that alter voltage dependence of activation cluster in the first half of the transmembrane domains and variants that yield no currents cluster in the second half of the transmembrane domain. None of the variants in the intracellular domains were associated with dominant functional features or dominant inheritance pattern of MC.

Our data help provide an initial estimate of the anticipated inheritance pattern based on the location of a novel variant and shows that systematic functional characterisation can significantly refine the assessment of risk of an associated inheritance pattern and consequently the clinical and genetic counselling.

**Author affiliations:**

1 MRC International Centre for Genomic Medicine in Neuromuscular Diseases, Department of Neuromuscular disease, UCL Queen Square Institute of Neurology, London, UK

2 AGE Research Group, NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle upon Tyne, UK

3 Atkinson Morley Neuromuscular Centre, Department of Neurology, St Georges University Hospitals NHS Foundation Trust, London, UK

4 Neurogenetics Unit, UCL Queen Square Institute of Neurology, London, UK

5 Department of Clinical Neurophysiology, King’s College Hospital, London, UK
6 Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK

7 Department of Pharmacology, UCL School of Pharmacy, London, UK

Correspondence to: Roope Männikkö
MRC International Centre for Genomic Medicine in Neuromuscular Diseases, Department of Neuromuscular disease, UCL Queen Square Institute of Neurology, London, UK
E-mail: r.mannikko@ucl.ac.uk

Running title: ClC-1 functional data in diagnosis of MC

Keywords: skeletal muscle channelopathy; chloride channel; myotonia congenita; ClC-1; CLCN1

Abbreviations: DM = Myotonic Dystrophy, MC = Myotonia congenita
Introduction

Myotonia congenita (MC) is the most common skeletal muscle channelopathy. It is caused by a reduction in the repolarizing chloride current, resulting in an increase in the excitability of the muscle membrane, leading to a delay in terminating muscle contraction following voluntary activity. This manifests clinically as stiffness and rigidity of affected muscles. MC has dominant and recessive forms, both caused by mutations in CLCN1 that result in reduced function of the encoded skeletal muscle chloride channel ClC-1. Sequencing of CLCN1 has become integral to confirming MC diagnosis following clinical assessment. However, it is important that myotonia is not erroneously attributed to an identified CLCN1 variant as myotonia can also be caused by Myotonic Dystrophy (DM)- a multisystem and potentially lethal disorder, and by gain-of-function mutations of the skeletal muscle sodium channel Na\textsubscript{v}1.4 (encoded by SCN4A). Mutations in distinct myotonia-associated genes (CLCN1, SCN4A, DMPK, CNBP) can co-occur in a patient and modify the presentation compared to a patient carrying a single gene mutation.

ClC-1 is a homodimer. Each subunit contains its own chloride-selective pore and is composed of 18 intramembrane \( \alpha \)-helices (conventionally numbered A to R) organised in two topologically related repeats with opposite membrane orientations, and an intracellular domain with two cystathionine beta-synthase (CBS) repeats. The chloride selective pores can be gated individually or concurrently, in processes known as fast and slow gating respectively. Both gates are opened by membrane depolarization. ClC-1 voltage sensitivity arises from the interaction of the channel with chloride ions.

Interpretation of the clinical significance of a ClC-1 variant can be difficult as MC exhibits intra- and interfamilial variability in the phenotype, severity and penetrance. In addition, it is currently difficult to accurately predict pathogenicity or inheritance of a novel variant based purely on the amino acid change and its location in the ClC-1 channel.
Functional assessment of mutations associated with MC has revealed that they either reduce functional expression or shift the voltage dependence of channel activation towards depolarized voltages, thereby reducing the chloride current at physiological voltages. A mutant subunit can show dominant negative effects upon co-expression with wild-type (WT) subunits, typically by shifting the voltage dependence of activation of the heterodimeric channel to depolarized voltages. Variants that show dominant negative effects in functional expression analysis are typically associated with dominant inheritance of MC while variants without dominant negative effects are associated with recessive inheritance.

To enable accurate use of functional data in a clinical diagnostic setting a correlation between distinct functional and clinical features needs to be established. This is currently complicated by phenotypic variability but also by heterogeneity in the methodology of the acquisition of genetic, clinical and functional data that often does not allow direct comparison of distinct functional features with the inheritance data between studies. In addition, some variants are found in both dominant and recessive pedigrees, suggesting that the correlation between functional features and the inheritance pattern is not linear. Finally, in some cases the functional data do not match the predicted pathogenicity and inheritance data. Thus, an evidence-based guide for assessment of pathogenicity and inheritance pattern based on specific functional features of ClC-1 variants is needed for purposeful clinical and genetic counselling.

We use functional expression to inform the diagnosis and genetic counselling in patients with MC. Here we report analysis of the correlation of the functional properties of 95 distinct missense variants with the reported inheritance pattern of 223 probands in a diagnostic service setting and assess the implications for the use of functional data to improve genetic counselling in MC.
Materials and methods

Ethics

The study was conducted as part of a service evaluation of the NHS England Highly Specialised Muscle Channelopathy Service at the National Hospital for Neurology and Neurosurgery. No procedures were performed outside of routine clinical care. The oocytes were recovered from *Xenopus laevis* toads in accordance with the Animals (Scientific Procedures) Act 1986.

Genetics

The diagnostic molecular genetics laboratory at the National Hospital for Neurology & Neurosurgery is the UK national centre for MC genetic testing. Since 2007 this consists of sequencing all 23 exons of *CLCN1* plus flanking intronic regions, or targeted sequencing of specific exons for relatives of individuals in whom variants have already been identified. For samples processed prior to 2007, it was routine for initial sequencing to be of mutation hotspots only. At least the proband subsequently underwent full sequencing of all *CLCN1* exons apart from the few circumstances where it was not possible to obtain DNA to do so. In cases where no mutations are found, a single recessive mutation is identified or a homozygous mutation is identified, Multiplex Ligation-dependent Probe Amplification is performed to assess for exon deletions or duplications. Whenever possible, the inheritance and allelic distribution of the variants is investigated by sequencing *CLCN1* in family members. Sequencing of *SCN4A* (full gene or hotspots), DM1 and DM2 retest was triggered after a ClC-1 variant was identified if the phenotype was atypical or it was uncertain if the *CLCN1* variant could account for dominant MC. In some samples *SCN4A* and *CLCN1* were screened in parallel.

DNA was extracted from blood using standard methods. Bidirectional direct DNA sequencing was performed using a Big Dye Terminator sequencing kit [Applied Biosystems
and a 3730 automated DNA sequencer (ABI). DNA sequences were analysed using version 2.5 SeqScape Analysis software (ABI). All 23 CLCN1 exons are compared to larger databases including 1000 genomes, dbSNP, ExAC and Exome Variant Server.

Clinical and genetic assessment of clinical inheritance pattern

The CLCN1 variants in each pedigree were assigned as dominant, recessive or sporadic, based on available demographic, clinical, electrophysiological and genetic data that were collected from referral forms and/or clinic notes (Supplementary Table 1-3, Table 1-2). Dominant variants were single variants sufficient to cause the MC phenotype and associated with parent to child transmission. The inheritance pattern of some dominant variants was specified “with variable penetrance” a) when the proband’s parents self-reported as asymptomatic but one was found to have the variant and clinical or electrographic myotonia on examination or b) in families with no known history of consanguinity, parents self-reported as asymptomatic and a nephew, niece, aunt, uncle or half-sibling was reported to be affected. Recessive variants were found in homozygosity or compound heterozygosity and associated with asymptomatic parents. Sporadic variants were found in isolation in probands with asymptomatic parents and no other family history of MC.

As expected at service level, the phenotyping and genotyping data for family members was not always complete. In Supplementary Tables 1-3 we specify if the assessment of inheritance pattern was confirmed by segregation of the variant with the clinical symptoms or if it was based on reports. When a family history was not available or was insufficient to determine the inheritance pattern, the variant is listed as unknown (Supplementary Table 1-3, Table 1-2). Some variants were classified as “uncertain pathogenicity” as specified in the Results.
**Molecular biology**

The mutations were introduced into WT *CLCN1* cDNA by Quikchange site-directed mutagenesis (Agilent). Successful mutagenesis was confirmed by sequencing the entire insert. The mRNA was transcribed from MluI linearized vector using mMessageMachine SP6 kit (Ambion).

**Xenopus laevis oocytes**

Oocytes were extracted from adult female *Xenopus laevis*, isolated after incubation with 2 mg/ml Collagenase Type A (Roche) in OR-2 (in mM): NaCl 82.5, KCl 2, MgCl₂ 1, HEPES, and injected with 2.5 ng WT or mutant mRNA. The heterozygous condition is simulated by injecting a 1:1 mixture of WT and mutant mRNA. The oocytes were incubated in Modified Barth’s solution (in mM): NaCl 88, KCl 1, MgSO₄ 1.68, HEPES 10, Ca(NO₃)₂ 0.47, NaHCO₃ 2.4, CaCl₂ 0.41, supplemented with penicillin and streptomycin routinely for 30-72 hrs at ~15°C before electrophysiological recordings. Each variant was studied in more than one batch of oocytes.

**Electrophysiology**

Two-electrode voltage clamp experiments were performed using GeneClamp 500B, DigiData 1200 or 1550 Interface, and Clampex software (all Axon Instruments) at room temperature in ND96 extracellular media (in mM): NaCl 96, KCl 2, MgCl₂ 1, HEPES 5, CaCl₂ 1.8, pH 7.4. Recording electrodes were filled with 3 M KCl and had a tip resistance <1 MΩ. Data were filtered at 1 kHz and sampled at 5 kHz.

From a holding voltage of -80 mV, an activating pre-pulse step to +60 mV for 250 ms was applied before test voltage steps ranging from -150 mV to +190 mV in 10 mV increments for 250 ms, followed by a tail voltage step to -100 mV. For most cells the same protocol was also applied with a holding voltage of -40 mV as well as an additional protocol where the holding
voltage was -80 mV and the pre-pulse step taken to -140 mV. These protocols are referred to as $V_h=-40$mV and $V_{pp}=-140$mV, respectively.

**Data analysis**

Data analysis and presentation were prepared using Clampfit (Axon instruments), Origin (OriginLab) and Excel (Microsoft) software.

The tail currents were routinely measured 4ms after the test pulse. The current-voltage relationship was fitted with Boltzmann equation: $I(V) = I_{max} / (1 + \exp((V_{1/2} - V)/V_c)) + C$, where $I_{max}$ is the amplitude of the fit, $C$ the offset current, $V_{1/2}$ the voltage at which the current is $(I_{max} + C)/2$ and $V_c$ the slope factor. We fixed the value of $C$ in the fitting process to the baseline current level at the most hyperpolarized voltages. In some cases two Boltzmann equations were required to fit the data: $I(V) = C + I_{max} \times \left( A / (1 + \exp((V_{1/2(1)} - V)/V_{c1})) + (1-A)/(1 + \exp((V_{1/2(2)} - V)/V_{c2})) \right)$, with $C$ and $I_{max}$ as above while $A$, $V_{1/2(1)}$, $V_{c1}$ and $(1-A)$, $V_{1/2(2)}$, $V_{c2}$ are the fraction, the voltage of half-maximal activation and the slope factor of the first and second Boltzmann component, respectively. The time constant of activation was assessed by fitting a two-component exponential equation to data following settling of capacitive transients, and the weighted average of time constants is presented.

Cells without a clear component of activation that could be described with a Boltzmann equation and with tail current amplitude <1 µA following a step to +80 mV were considered devoid of functional ClC-1 channel expression.

The data are presented as mean ± standard error of the mean (SEM) unless otherwise stated. To assess if clustering of the variants across the functional and structural groups was significant, we used a two-tailed Fisher’s test.
Data availability

Functional data are available upon reasonable request to the corresponding author. The clinical and genetic data are not publicly available.

Results

Genetic and clinical overview of the cohort

Our cohort comprised 223 probands referred for genetic testing for MC in whom $CLCN1$ variants were identified. A total of 115 distinct mutations were identified in the cohort, 95 of which were missense while 20 were non-missense (truncating, frameshifting, intronic, duplications, deletions or silent). The non-missense variants were included in the cohort only if they were compound heterozygous with missense mutations.

A single heterozygous variant was found in 116, homozygous variant in 27 (one with two homozygous variants), compound heterozygous variants in 75, and more than two variants in five probands (Supplementary Table 1). In total 309 variants (Supplementary Table 1-3), of which 263 were missense (Supplementary Table 2), were found in the cohort and were assigned an inheritance pattern. For the missense variants this was either dominant (81), sporadic (21) or recessive (74) (Supplementary Table 2). For a further 54 missense variants, family history was unavailable or insufficient to determine the inheritance pattern. For 33 missense variants the assessment of pathogenicity or inheritance was complicated by co-allelic $CLCN1$ variants, the presence of variants in other myotonia-associated genes, by the variant not segregating with MC symptoms, or by reported dominant inheritance in compound heterozygous probands where it could not be determined which of the variants was associated with dominant inheritance. These variants were assigned “with uncertain pathogenicity”. For 50 of the missense variants in the cohort with recessive or dominant inheritance pattern the assessment was based on both clinical and genetic segregation data and for 105 variants this was based on
clinical symptoms only (Supplementary Table 2). Of the 33 pedigrees with dominant inheritance and confirmed segregation, 6 met our criteria for variable penetrance (Supplementary Table 2).

Seventy-eight of the variants were found in a single pedigree only (64 missense variants) (Supplementary Tables 1-3). The most common variant, G230E, was identified in 40 pedigrees. Eight variants were found associated with more than one inheritance pattern (dominant, sporadic, recessive), of which three (G285E, F307S and A313T) were associated with both recessive and dominant inheritance. The only variant with genetic segregation data available to confirm association with both dominant and recessive inheritance was G285E. Variable penetrance has been reported previously for G285E.18,19,26

To our knowledge, 34 of the missense variants have not been previously reported as associated with MC and a further 28 have been reported but not functionally characterised.

**Functional assessment and classification of ClC-1 variants**

The effect of the *CLCN1* missense variants on ClC-1 channel function was tested in the *Xenopus laevis* oocyte expression system for the 95 missense variants. The $V_{1/2}$ for WT channels was $-34.2 \pm 0.6$ mV ($n=308$) (Figure 1, Supplementary Table 4). As the $V_{1/2}$ of cells expressing WT channels was variable (standard deviation (SD)= 10.4 mV, range -68.6 mV to -7.8 mV), we assigned a cut-off voltage ($V_{1/2}$ for the WT channel ±1.5*SD= -18.6 mV) to decide if the $V_{1/2}$ was WT-like or pathogenic (Figure 1C). Using this cut-off voltage, the well-known pathogenic variant F167L with a modest positive shift in the voltage dependence of activation$^27$ ($V_{1/2}$= -17.7 mV, Supplementary Table 4) was classified as pathogenic while variants with $V_{1/2}$ negative to that were not. One variant, H664P, activated at more hyperpolarized voltages than 1.5*SD cut-off (Supplementary Table 4). In the absence of loss-of-function effects this variant was not considered pathogenic.
The current amplitude of WT channels was also variable (-6.3±0.2 µA, SD=3.6 µA, range -0.5 to -30 µA). Twenty-five variants did not show any chloride currents (Supplementary Table 4) and for five variants with WT-like voltage dependence of activation (A221E, H369P, V397D, F413C, E422K) and one variant with shifted voltage dependence of activation (W303R) many of the oocytes did not show currents (Figure 1, Supplementary Table 4) and the mean amplitude of the currents from those oocytes that yielded currents was less than the mean ± SD for oocytes expressing WT channels (Figure 1E). Although not displaying complete loss-of-function these variants were considered pathogenic by reducing functional expression of the channel.

Most (91/95) of the channel variants could be described as having WT-like features (25 variants), no or reduced chloride currents (31 variants) or chloride currents with shifted voltage dependence of activation (35 variants) (Figure 1, Supplementary Table 4).

Functional properties of extraordinary ClC-1 variants

Four variants showed properties that could not be described by reduced current amplitude or shifted voltage dependence of activation alone.

Two variants (L332R and P342L) showed depolarization activated currents but it was difficult to describe the voltage dependence of activation with a Boltzmann equation. In addition, the tail current amplitude declined when studied with pre-pulses to hyperpolarized voltages ($V_{pp}=-140$ mV) but increased when using a more depolarized holding voltage ($V_h=-40$mV) (Figure 2A,D,E). The voltage dependence of activation of WT channels too is clearly dependent on the voltage protocol (Figure 2A,C). To compare WT, L332R and P342L behaviour the currents for each cell were normalised to the tail current amplitude following a voltage step to $+100$ mV using the $V_h=-40$mV protocol. In response to a voltage step to 0 mV using the $V_{pp}=-140$ mV protocol the normalised WT channel activity was 58%, but only 31%
for L332R and 24% for P342L channels, demonstrating reduced activity for mutant channels at physiological voltages (Figure 2D,E).

Two variants (M485K and R421C) showed currents at hyperpolarized voltages (Figure 2B, F). M485K channels also showed depolarization-activated currents but with a voltage dependence of activation that was shifted to depolarized voltages (Supplementary Table 4). Oocytes expressing R421C channels showed small depolarization-activated currents (mean tail current amplitude $-1.1\pm0.1$ µA) with shifted voltage dependence of activation (Supplementary Table 4). The current amplitude at $-120$ mV was $-1.8\pm0.3$ µA for M485K cells, $-0.9\pm0.2$ µA for R421C channels but $-0.4\pm0.05$ µA for WT cells ($V_{pp}=-140$mV protocol).

**Assessment of dominant negative effect of ClC-1 variants**

To simulate the heterozygous condition of the patient and to assess the inheritance pattern of the variant, mRNA encoding mutant and WT subunits were co-injected into oocytes (Figure 3). We indicate the simulated heterozygous condition by adding the suffix “het” to the variant name, e.g. F167Lhet.

Twenty-three of the 31 variants that showed no or reduced currents when expressed alone showed currents with WT-like voltage dependence of activation in simulated heterozygous conditions (Figure 3E, Supplementary Table 4). The current amplitude in simulated heterozygous condition was not reduced much below 50% of current amplitude from oocytes expressing WT channels (Figure 3F).

Eight variants with no or reduced currents as homomers produced currents with altered voltage sensitivity of activation upon co-expression (Figure 3B, Supplementary Table 4). The voltage dependence of the heterozygous channels was better fit with Boltzmann equation with two rather than with one component. The component that activated at more hyperpolarised voltages had a $V_{1/2}$ similar to that of WT channels (Supplementary Table 4), consistent with these currents being produced by a mixed population of WT homomers and WT/mutant dimers.
For all variants with a shift in the voltage dependence of activation, the $V_{1/2}$ of the simulated heterozygous channel was less positive than that of the homomeric mutant channel, except for the F297S variant that showed a greater shift in the $V_{1/2}$ in simulated heterozygous than in homomeric form (Figure 3E, Supplementary Table 4). For 23 variants the $V_{1/2}$ was positive to the voltage set as a cut-off for assigning pathogenicity in homomeric conditions. This suggests that in heterozygous conditions the current amplitude is significantly reduced at physiological voltages. For 12 variants the voltage dependence in simulated heterozygous conditions was WT-like.

Thus, in total 35 variants that showed pathogenic changes in homomeric condition did not show dominant negative effects on channel function in simulated heterozygous condition suggesting recessive inheritance, while 31 variants showed a shifted voltage dependence of activation, suggesting dominant inheritance.

The voltage dependence of activation of P342Lhet and L332Rhet channels could be fitted with a Boltzmann equation and was WT-like (Supplementary Table 4, Figure 3). However, when using the $V_{pp}=-140\text{mV}$ protocol the voltage dependence of activation was shifted $\sim+30\text{mV}$ compared to WT, suggesting that the simulated heterozygous form retains an increased sensitivity to voltage protocols (Figure 3). The current amplitude at hyperpolarized voltages relative to the amplitude at depolarized voltages was larger for M485Khet and R421Chet channels compared to WT channels (Figure 3). The voltage dependence of the depolarization-activated current was shifted for M485Khet and WT-like for R421Chet channels (Supplementary Table 4).
Correlation of functional properties with inheritance patterns of clinical symptoms

We next analysed how the distinct functional features of the 95 missense variants (“Functional” column Table 1-2, Supplementary Table 4) correlates with the inheritance pattern assigned by analysing the clinical and genetic features of the 223 probands (“Clinical / Genetic” column in Table 1-2, Supplementary Table 2). To ensure equal weight for each variant, the variants that were associated with more than one inheritance category were assigned a fractional value based on the frequency they appeared in the distinct categories (“Clinical / Genetic” column in Table 1-2). For example, A313T was found in twelve probands: nine dominant, one sporadic, and one recessive pedigree and in one pedigree the inheritance was unknown. It was assigned with 0.75 dominant, 0.083 sporadic, 0.083 recessive and 0.083 unknown inheritance.

WT-like functional features suggest the variant is not associated with MC. Accordingly, the pathogenicity was uncertain for 39% of these variants and for a further 24% the data were insufficient to confirm the inheritance pattern. For only 37% of these variants was clinical data sufficient to assess the inheritance pattern: two probands (6%) were sporadic carrying a lone heterozygous variant with asymptomatic parents and the remaining variants (31%) were found in recessive pedigrees.

For variants with recessive functional features the family history was available to confirm recessive inheritance for 58%. For 28% the inheritance pattern could not be confirmed and for 11% the association with MC was uncertain. All probands with unknown inheritance pattern and all but one of the probands with uncertain association with MC carried compound heterozygous CLCN1 variants. Only two variants with recessive functional features were found as a lone mutation. G285V was found in heterozygosis in a dominant pedigree with a parent
carrying the variant and displaying mild myotonia. DM1, DM2 and SCN4A mutations were excluded in the proband. In another pedigree the association of a lone F167L variant with MC was uncertain as it was identified together with a known pathogenic SCN4A variant.

The non-missense variants were compound heterozygous with missense variants as per inclusion criteria. Consistently, when the inheritance pattern of clinical symptoms could be determined it was always recessive (Supplementary Table 3). Pathogenicity of some of the non-missense variants included in this cohort remains to be determined.

For missense variants with dominant functional features the inheritance pattern was dominant for 41%, sporadic for 11%, recessive for 19%, unknown for 21% and uncertain for 8% of variants. For 8/10 pedigrees where the association with MC was uncertain the inheritance was reported dominant but the proband carried two CLCN1 variants and it could not be confirmed which variant was dominant. Two other uncertain cases include probands where a heterozygous A313V or G285E variant occurred together with a known pathogenic SCN4A variant.

Two of the variants with a mild positive shift in $V_{1/2}$ in the simulated heterozygous condition compared to the cut-off voltage, A313T and P480S (Supplementary Table 4), were identified mainly in dominant pedigrees (75% and 50%, respectively). In contrast, all variants with shifted voltage dependence of activation in the homomeric condition but WT-like voltage dependence in the simulated heterozygous condition were identified in recessive pedigrees. This suggests that the cut-off $V_{1/2}$ value was useful in discerning variants associated with recessive inheritance from variants with a risk of dominant inheritance.

For statistical analysis of the correlation of functional and inheritance data we excluded the variants with insufficient information to determine the inheritance pattern (Figure 4). The percentage of variants with uncertain association with MC was significantly higher for variants with WT-like functional features (51%) than variants with recessive (16%, $p<0.05$) or
dominant (10%, p<0.01) functional features. The percentage of variants with recessive inheritance pattern of clinical symptoms was significantly higher for variants with recessive functional features (80%) than variants with WT-like (41%, p<0.01) or dominant (24%, p<0.001) functional features. The percentage of variants associated with a dominant inheritance pattern of clinical symptoms was significantly higher for variants with dominant functional features (52%) than variants with WT-like (0%, p<0.001) or recessive (4%, p<0.001) functional features. Sporadic variants showed dominant or WT-like but not recessive functional features.

Variants with prominent loss-of-function following a hyperpolarizing pre-pulse (L332R, P342L) were found in pedigrees with sporadic inheritance, suggesting that a single variant may be sufficient to cause clinical symptoms. The M485K variant with hyperpolarization-activated currents and shifted voltage dependence of depolarization activated currents in the simulated heterozygous condition was found in a large pedigree with recessive inheritance. The inheritance pattern for R421C with hyperpolarization-activated currents and WT-like depolarization activated currents in the simulated heterozygous condition was also recessive, with an asymptomatic heterozygous carrier among the parents. F297S, the only variant with $V_{1/2}$ more positive in the simulated heterozygous than in the homomeric condition, was only found in dominant pedigrees.

**Alternative pathogenic mechanisms of variants with WT-like voltage dependence of activation**

More than a quarter of the studied variants show WT-like expression levels and voltage dependence of activation, despite being found in patients with clinical features suggestive of MC. Accordingly, for many of these variants the association with myotonia was uncertain, but in several pedigrees the clinical and genetic data support an association with MC. We
investigated if functional features other than current amplitude or voltage dependence of activation could indicate alternative pathogenic mechanisms.

Two variants, A331S and F333L showed a WT-like voltage dependence of activation following a depolarizing pre-pulse (Supplementary Table 4). However, both showed clearly reduced rates of activation (Figure 5A,B). Consequently, following a hyperpolarizing pre-pulse ($V_{pp}$=-140mV), the voltage dependence of activation was shifted $\sim$+25 mV compared to WT channels (Figure 5C). A331S was found in a proband with P480fs frameshift mutation with asymptomatic parents while F333L was found in homozygosis in a pedigree where the parents were confirmed heterozygous asymptomatic carriers. These data suggest that slow activation may contribute to MC with recessive inheritance.

One variant with WT-like voltage dependence of activation, L587V, showed an accelerated rate of activation and closing (Figure 5A,D,E). The variant was found in homozygosis in two pedigrees with confirmed asymptomatic parents, suggesting that the variant contributes to recessive MC. Accelerated closing is a loss-of-function feature that results in reduced increment in current amplitude at physiological voltages when switching from hyperpolarizing to depolarizing pre-pulse conditions. For WT channels the mean open probability at -60 mV increases from 0.17 to 0.47 (276%) when switching from hyperpolarizing ($V_{pp}$=-140mV protocol) to depolarizing ($V_{h}$=-40mV protocol) pre-pulse condition. Respective values for L587V are 0.24 ($V_{pp}$=-140mV) and 0.31 ($V_{h}$=-40mV) (29% increase, $p<0.001$ for both protocols (Mann-Whitney test)). These data indicate that a lack of increase in ClC-1 channel activity at physiological voltage following electrical activation of the muscle may contribute towards myotonia.

**Discussion**

Our functional data for 95 ClC-1 missense variants identified in 223 myotonic probands provide strong support for an evidence-based guide for the use of functional data in the
diagnosis of MC. Thirty-four of these CLC-1 variants were novel and 28 had not previously been functionally characterised, some of which showed new pathogenic mechanisms that have implications for understanding the function of the CLC-1 channel. We also identified clustering of variants with distinct functional features on the CLC-1 structure.

**Variants with WT-like functional features**

Consistent with the lack of detrimental effects in functional analysis, variants with WT-like functional features are significantly more likely to have uncertain association with MC compared to variants with pathogenic functional features. However, an association with MC is not excluded when a variant is functionally WT-like based on voltage dependence and current amplitude alone. Other loss-of-function features may contribute, such as alterations in rates of channel activation or deactivation (Figure 5) or splicing, as shown for V327L variant.\(^\text{28}\) Another variant c.1222A>G (P408A) creates an AG dinucleotide that activates a cryptic acceptor site and potentially alters splicing of *CLCN1* mRNA (Human Splicing Finder). Potential splicing defects could be assessed by studying patient *CLCN1* mRNA or with the minigene assay.\(^\text{29}\) It is also possible that some variants with WT-like functional features but classified as recessive (H29P and S70V) are in fact innocuous as they were compound heterozygous with variants with dominant functional features (P234T and F307S, respectively). The classification as recessive may be a result of variable penetrance of the dominant variants, as shown previously for F307S variant. Finally, it is possible that the pathogenic mechanism involves disruption of muscle-specific modulation of the channel that cannot be detected in the *Xenopus* oocyte expression system. CLC-1 modulation involves intracellular domains\(^\text{30,31}\) where many of the variants with WT-like functional features are located (Table 1, see below).

When a variant with WT-like functional feature was associated with MC the inheritance pattern was never dominant (Figure 4). However, two variants with WT-like functional features (A402V and R669C) were found as a lone mutation in sporadic pedigrees with asymptomatic
parents. It remains to be determined if and how these variants with no detectable pathogenicity in functional assay are the sole cause of myotonia in these probands.

Taken together our data suggests that variants with WT-like functional properties carry a significant risk of uncertain association with MC and consequently alternative genetic causes of myotonia, e.g. *SCN4A* mutations and DM should be excluded as a priority, particularly when a WT-like variant is found in isolation.

**Variants with recessive functional features**

Variants with recessive functional features were mainly associated with recessive MC (Figure 4). In keeping with this, all probands with functionally recessive variants for whom the clinical inheritance pattern was unknown had compound heterozygous variants. Only one variant (G285V) was found in isolation in a pedigree with dominant family history. The mechanism of dominant inheritance of this variant remains to be determined.

These data suggest that variants with recessive functional properties should be reported as recessive and that finding these variants as the sole heterozygous variant should trigger investigations into alternative mechanisms of myotonia.

**Variants with dominant functional features**

Fifty-two percent of variants with dominant functional features were found in pedigrees with dominant inheritance of clinical symptoms (Figure 4B), 14% in heterozygous probands with sporadic inheritance of MC and a further 10% in dominant pedigrees although classified with “uncertain association with MC” as they were compound heterozygous with another *CLCN1* variant and segregation data was not available to confirm which variant was associated with dominant inheritance or with a known pathogenic *SCN4A* variant. It is likely that the *CLCN1* variants modify the presentation of *SCN4A* variants in these probands.8-11
The clinical inheritance of 24% of the functionally dominant variants was recessive. Although for most of these variants the shift in the voltage dependence of activation was modest, S289I, a variant with one of the largest shifts was found in a recessive pedigree with a reportedly asymptomatic parent. Dominant inheritance had variable penetrance in 7% of variants, including the most common dominant variant G230E that was found in two apparently unaffected individuals. In our cohort variants with dominant functional features had greatly increased risk of dominant inheritance compared to those with recessive or WT-like functional features. However, it is possible that none of the variants with dominant functional features has full clinical penetrance.

**Structure-function considerations**

When plotted on the ClC-1 primary structure a disproportionately high number of variants (48%) were located in the first of the roughly identical halves of the transmembrane domain (TM1) of ClC-1 subunit (helices B-I and the IJ-linker, residues 111-344) but only 19% of variants were found in the intracellular N- and C-termini (1-110, 586-988) (Table 1-2, Figure 6). Seventy-nine percent (37/47) of the variants that shifted the voltage dependence of activation in homomeric or simulated heterozygous condition, including the variants with extraordinary functional properties, are located in TM1, while a further eight (17%) were on the second half of transmembrane domain (TM2) (residues 345-585) and two variants (4%) were intracellular (Figure 6A-C). Of the variants with shifted voltage dependence of activation in simulated heterozygous condition 84% (26/31) were found on TM1 and the remaining 16% on TM2. In contrast, 16/23 (70%) of the variants with recessive functional features without shift in voltage dependence of activation in homomeric condition were found on TM2, six in TM1 (26%) and a single variant was intracellular. Finally, WT-like variants were predominantly found in intracellular termini (60%, 15/25), while five variants were found in TM1 and TM2 each. This distinct, predominant distribution of variants with dominant,
recessive without shift in voltage dependence of activation as homomers and WT-like functional features in TM1, TM2 and intracellular domains, respectively, was significant (Figure 6B,C) and helps guide preliminary predictions on functional features and consequently on pathogenicity and inheritance pattern of novel variants. However, functional characterisation is still necessary as different substitutions of a single residue can have drastically different effects (e.g. M485V and M485K). Nevertheless, it is notable that in our cohort none of the variants found in the intracellular domains were associated with dominant inheritance or functional features. Therefore, in patients with a lone intracellular ClC-1 variant, alternative mechanisms of myotonia should be excluded as a priority.

TM1 is mainly located towards the intracellular end of the intramembrane domain where the chloride ions are found in the selectivity filter pathway (Figure 6D). The voltage dependence of ClC-1 channel activation is sensitive to Cl\(^-\) concentration and arises from interactions with the channel and the ion.\(^{14-16}\) It is thus likely that the dominant variants localised towards the intracellular side shift the voltage dependence of activation by altering these interactions. The TM1 also forms most of the subunit interface (Figure 6E), suggesting that mutations in one subunit can affect the chloride conducting pathway in the neighbouring subunit through this interface. F297S, the only variant with voltage dependence of activation showing larger shift in simulated heterozygous than in homomeric condition, affects a residue located at the subunit interface with the main chain of the two F297 residues in close contact (Figure 6G). Functional data suggests that a symmetric F297S channel shows a smaller shift in voltage dependence of channel activation than a F297/F297S heterodimer and supports the notion that the functional effect of a mutation in one subunit is physically transduced to the second subunit through the subunit interface (Figure 6G).

TM2 is located mainly towards the extracellular side of the intramembrane domain, above the selectivity filter pathway. This may explain the lower frequency of variants that shift the
voltage dependence of activation. The variants with shifted voltage dependence in TM2 are located close to the Cl- ions (P480, G483, V536) or in the proximity of the TM1 of the neighbouring subunit (G523, G551, M560) (Figure 6D). TM2 also contains a cluster of recessive variants without shift in voltage dependence of activation in homomeric condition located above the selectivity filter (Figure 6D). It is not known if these variants reduce channel expression or if they prevent the permeation of chloride by obstructing the pathway. Absence of significant subunit interface between two TM2s may explain why the effect of a mutation in one subunit is not commonly transduced to the neighbouring subunit.

Mutations that showed currents at hyperpolarized voltages affect the residues R421 and M485 located just above the glutamate residue (E232) implicated as an external gate where other mutations with similar gating defects are found (Figure 6F). In particular R421 forms a salt bridge with D136 that when replaced by a glycine conducts hyperpolarization activated currents. These data imply that residues above the selectivity filter form a gate that prevents hyperpolarization activated currents.

The WT ClC-1 channels exhibit a low activity state ($V_{1/2}$~5mV) induced by hyperpolarization and a high activity state ($V_{1/2}$~45mV) induced by depolarization, thereby displaying hysteresis in its voltage dependence. Transition from low to high activity state would allow for larger increase of ClC-1 currents at physiological voltages in response to prolonged muscle activity compared to a model where ClC-1 channel activity follows a constant voltage dependence. The notion that some mutants (L332R and P342L) showed more pronounced defects in response to hyperpolarizing pre-conditions suggests that the properties of the mutant channels should be assessed using both high and low activity protocols. This idea is reinforced by the observation that two mutant channels (A331S and F333L) with reduced rate of activation when measured using hyperpolarized pre-pulses showed WT-like voltage dependence of activation when studied with protocols that incorporated a depolarizing pre-
The unusual voltage dependence of activation of L332R and P342L channels following hyperpolarization may be a result of ultraslow activation (Figure 2). All of these variants are found in the linker that connects helices I (TM1) and J (TM2) at the extracellular surface of the channel. The IJ-linkers of the two subunits are in close contact but the tip of the linker (L332/F333L) reaches to proximity of residues important for channel gating (R421) (Figure 6F). Our data suggest that the IJ-linker is important for determining the rate of channel activation.

One of the variants in our cohort (L587V) showed reduced shift between low to high activity states, a feature that can be attributed to accelerated channel opening and closing. L587V was found in homozygosis in two MC pedigrees suggesting that the distinct kinetic features contribute towards myotonia and that a normal shift from low to high activity state upon electrical activation of the muscle may be important for preventing myotonia. The slow component of WT-channel closure may be a result of ([Cl\(^-\)]-dependent) stabilization of the open state that shifts the voltage dependence of activation to more hyperpolarized voltages. The location of L587 suggests that conformational changes that stabilize the open state occur at the intracellular entrance of the selectivity filter pathway (Figure 6G).

**Implications for clinical practice**

One aim of this work was to improve the genetic counselling that we can provide to patients. The first application of the data is that even without functional characterisation an initial approximate, but evidence-based estimate of the risk of an associated dominant inheritance pattern can be drawn based on the location of the variant (Figure 6A). In particular, variants with dominant functional features are clustered in TM1 and variants with recessive functional features without shift in voltage dependence of activation are clustered in TM2. None of the variants in intracellular domains in our cohort were associated with dominant family history or dominant functional features suggesting that for variants in intracellular domains other causes
of myotonia should be excluded as a priority. The location-based estimate can be refined by closer investigation of the location in the 3D structure of the ClC-1 channel (Figure 6).\textsuperscript{32,34} Second, once functional characterisation is performed, this risk of an associated dominant inheritance pattern can be significantly refined (Fig 4).

Functional assessment of pathogenicity and inheritance for 95 ClC-1 variants found in 223 MC pedigrees shows a clear correlation between recessive and dominant functional features with respective inheritance patterns of clinical symptoms. It provides strong support and an evidence-based guide for the use of functional analysis in the genetic diagnosis and counselling of MC. Accurate diagnostic and genetic counselling may help guide the therapeutic strategies of patients with MC.\textsuperscript{35} We believe our evidence-based guide is translatable to laboratories using the same protocols for functional analysis. Laboratories using different protocols will need to perform a correlation analysis between functional features and the inheritance pattern of clinical symptoms to establish their own criteria to classify the functional features. The data provided in this manuscript serves as a reference for the inheritance pattern of 95 variants to help establish such correlations.

**Funding**

The work was supported by UCLH NIH Biomedical Research Centre and by the UK MRC. KS was supported by an MRC Clinical Research Training Fellowship (MR/M01827X/1) and by U FP7/2007-2013 program Grant No 2012-305121 “NeurOmics”. E.M. received funding from a Wellcome Clinical Research Career Development Fellowship (209583/Z/17/Z).
Competing interests

Authors report no competing interests.

Supplementary material

Supplementary material is available at Brain online.

References

1. Horga A, Raja Rayan DL, Matthews E, et al. Prevalence study of genetically defined skeletal muscle channelopathies in England. Neurology. 2013;80:1472-1475.

2. Bryant SH, Morales-Aguilera A. Chloride conductance in normal and myotonic muscle fibres and the action of monocarboxylic aromatic acids. The Journal of physiology. 1971;219:367-383.

3. Koch MC, Steinmeyer K, Lorenz C, et al. The skeletal muscle chloride channel in dominant and recessive human myotonia. Science (New York, NY). 1992;257:797-800.

4. George AL, Jr., Crackower MA, Abdalla JA, Hudson AJ, Ebers GC. Molecular basis of Thomsen's disease (autosomal dominant myotonia congenita). Nat Genet. 1993;3:305-310.

5. Bugiardini E, Rivolta I, Binda A, et al. SCN4A mutation as modifying factor of myotonic dystrophy type 2 phenotype. Neuromuscular disorders : NMD. 2015;25:301-307.

6. Binda A, Renna LV, Bosè F, et al. SCN4A as modifier gene in patients with myotonic dystrophy type 2. Scientific reports. 2018;8:11058.

7. Cardani R, Giagnacovo M, Botta A, et al. Co-segregation of DM2 with a recessive CLCN1 mutation in juvenile onset of myotonic dystrophy type 2. J Neurol. 2012;259:2090-2099.
8. Furby A, Vicart S, Camdessanche JP, et al. Heterozygous CLCN1 mutations can modulate phenotype in sodium channel myotonia. *Neuromuscular disorders : NMD*. 2014;24:953-959.

9. Kato H, Kokunai Y, Dalle C, et al. A case of non-dystrophic myotonia with concomitant mutations in the SCN4A and CLCN1 genes. *Journal of the neurological sciences*. 2016;369:254-258.

10. Maggi L, Ravaglia S, Farinato A, et al. Coexistence of CLCN1 and SCN4A mutations in one family suffering from myotonia. *Neurogenetics*. 2017;18:219-225.

11. Thor MG, Vivekanandam V, Sampedro-Castañeda M, et al. Myotonia in a patient with a mutation in an S4 arginine residue associated with hypokalaemic periodic paralysis and a concomitant synonymous CLCN1 mutation. *Scientific reports*. 2019;9:17560.

12. Miller C, White MM. Dimeric structure of single chloride channels from Torpedo electroplax. *Proceedings of the National Academy of Sciences of the United States of America*. 1984;81:2772-2775.

13. Dutzler R, Campbell EB, Cadene M, Chait BT, MacKinnon R. X-ray structure of a CIC chloride channel at 3.0 A reveals the molecular basis of anion selectivity. *Nature*. 2002;415:287-294.

14. Richard EA, Miller C. Steady-state coupling of ion-channel conformations to a transmembrane ion gradient. *Science (New York, NY)*. 1990;247:1208-1210.

15. Pusch M, Ludewig U, Rehfeldt A, Jentsch TJ. Gating of the voltage-dependent chloride channel CIC-0 by the permeant anion. *Nature*. 1995;373:527-531.

16. Rychkov GY, Pusch M, Astill DS, Roberts ML, Jentsch TJ, Bretag AH. Concentration and pH dependence of skeletal muscle chloride channel CIC-1. *The Journal of physiology*. 1996;497:423-435.
17. Pusch M, Steinmeyer K, Koch MC, Jentsch TJ. Mutations in dominant human myotonia congenita drastically alter the voltage dependence of the CIC-1 chloride channel. *Neuron*. 1995;15:1455-1463.

18. Fialho D, Schorge S, Pucovska U, et al. Chloride channel myotonia: exon 8 hot-spot for dominant-negative interactions. *Brain*. 2007;130:3265-3274.

19. Kubisch C, Schmidt-Rose T, Fontaine B, Bretag AH, Jentsch TJ. CIC-1 chloride channel mutations in myotonia congenita: variable penetrance of mutations shifting the voltage dependence. *Human molecular genetics*. 1998;7:1753-1760.

20. Mazon MJ, Barros F, De la Pena P, et al. Screening for mutations in Spanish families with myotonia. Functional analysis of novel mutations in *CLCN1* gene. *Neuromuscular disorders : NMD*. 2012;22:231-243.

21. Vindas-Smith R, Fiore M, Vasquez M, et al. Identification and Functional Characterization of *CLCN1* Mutations Found in Nondystrophic Myotonia Patients. *Human mutation*. 2016;37:74-83.

22. Wollnik B, Kubisch C, Steinmeyer K, Pusch M. Identification of functionally important regions of the muscular chloride channel CIC-1 by analysis of recessive and dominant myotonic mutations. *Human molecular genetics*. 1997;6:805-811.

23. Imbrici P, Maggi L, Mangiatordi GF, et al. CIC-1 mutations in myotonia congenita patients: insights into molecular gating mechanisms and genotype-phenotype correlation. *The Journal of physiology*. 2015;593:4181-4199.

24. Altamura C, Lucchiari S, Sahbani D, et al. The analysis of myotonia congenita mutations discloses functional clusters of amino acids within the CBS2 domain and the C-terminal peptide of the CIC-1 channel. *Human mutation*. 2018;39:1273-1283.

25. Parrock S, Hussain S, Issler N, et al. *KCNJ10* mutations display differential sensitivity to heteromerisation with *KCNJ16*. *Nephron Physiology*. 2013;123:7-14.
26. Stunnenberg BC, Raaphorst J, Deenen JCW, et al. Prevalence and mutation spectrum of skeletal muscle channelopathies in the Netherlands. Neuromuscular disorders : NMD. 2018;28:402-407.

27. Zhang J, Bendahhou S, Sanguinetti MC, Ptácek LJ. Functional consequences of chloride channel gene (CLCN1) mutations causing myotonia congenita. Neurology. 2000;54:937-942.

28. Lorenz C, Meyer-Kleine C, Steinmeyer K, Koch MC, Jentsch TJ. Genomic organization of the human muscle chloride channel CIC-1 and analysis of novel mutations leading to Becker-type myotonia. Human molecular genetics. 1994;3:941-946.

29. Ulzi G, Sansone VA, Magri F, et al. In vitro analysis of splice site mutations in the CLCN1 gene using the minigene assay. Mol Biol Rep. 2014;41:2865-2874.

30. Benetts B, Parker MW, Cromer BA. Inhibition of skeletal muscle CIC-1 chloride channels by low intracellular pH and ATP. The Journal of biological chemistry. 2007;282:32780-32791.

31. Hsiao KM, Huang RY, Tang PH, Lin MJ. Functional study of CLC-1 mutants expressed in Xenopus oocytes reveals that a C-terminal region Thr891-Ser892-Thr893 is responsible for the effects of protein kinase C activator. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2010;25:687-694.

32. Park E, MacKinnon R. Structure of the CLC-1 chloride channel from Homo sapiens. eLife. 2018;7.

33. Fahlke C, Riidel R, Mitrovic N, Zhou M, George AL. An aspartic acid residue important for voltage-dependent gating of human muscle chloride channels. Neuron. 1995;15:463-472.
34. Wang K, Preisler SS, Zhang L, et al. Structure of the human ClC-1 chloride channel. 

*PLoS biology.* 2019;17:e3000218.

35. Desaphy JF, Altamura C, Vicart S, Fontaine B. Targeted Therapies for Skeletal Muscle Ion Channelopathies: Systematic Review and Steps Towards Precision Medicine. *Journal of neuromuscular diseases.* 2021;8:357-381.
Figure legends:

Figure 1. Overview of functional properties of ClC-1 variants. (A) Representative traces of WT channel, a variant with WT-like functional features (M646T) and a variant with shifted voltage dependence of activation (S289G). From holding voltage of -80 mV, 250 ms pre-pulse step to +60 mV, 250 ms test voltage steps from -150 mV to +190 mV in 10 mV increments (only traces in response to pulses up to +60 mV are shown) and a tail voltage step to -100 mV were applied. Scale bars: 250 ms (x), 3 µA (y). (B) Voltage dependence of activation of WT (black), M646T (blue) and S289G (yellow) channels. Current at the beginning of tail voltage step was normalised to peak amplitude of the Boltzmann fit for each cell and the mean ± SEM normalized current data is shown. Solid lines show fit of Boltzmann equation to mean data. (C) Mean $V_{1/2} \pm$ SEM is shown for each variant. If the $V_{1/2}$ of the variant was depolarized relative to the cut-off voltage (WT ± 1.5*standard deviation red dashed vertical line) the variant was considered pathogenic. If the $V_{1/2}$ was to the left of the cut-off it was considered WT-like. (D) Representative current traces of a variant (A221E) with minimal ClC-1 currents. Scale bars as in (A). (E) Mean ± SEM tail current amplitude of variants with WT-like voltage dependence. Red bars show SD of WT current amplitude data. While most variants showed WT-like current amplitude, for five variants many cells did not express currents and when the currents were detectable the mean amplitude was outside the limits of WT ± SD. These variants were considered pathogenic due to reduced expression. Numbers are shown in Supplementary Table 4.
Figure 2. Functional properties of variants where the dysfunction could not be described by analysis of $V_{1/2}$ or current amplitude only. (A) Representative current traces of WT, L332R and P342L channels. Voltage protocol was as in 1A except that the holding voltage was -40 mV ($V_h$=-40 mV) (top row) or as in 1A but the pre-pulse step was to -140 mV ($V_{pp}$=-140 mV) (bottom row). Scale bars: 250 ms (x), 5 µA (y). (B) Representative current traces of R421C and M485K channels. Voltage protocol was as in 1A except that the pre-pulse step was to -140 mV. A & B. Traces in response to test pulses up to +60 mV are shown. Scale bars: 250 ms (x), 1 µA (R421C) or 3 µA (M485K) (y). (C) Data for WT channels is shown in response to test voltages (grey) or to tail voltage (black) using the $V_h$=-40 mV protocol (solid symbols) and $V_{pp}$=-140 mV protocol (open symbols). Data for each cell is normalised to current in response to (grey) or immediately after (black) a voltage step to +100 mV. Only a subset of WT cells was analysed (n=18). (D, E) Data for L332R (red) and P342L (blue) is shown for $V_h$=-40 mV (solid) and $V_{pp}$=-140 mV (open) protocols. Data is normalised as in C. N(L332R)=13 and n(P342L)=11. WT data as in C is shown in black. (F) Mean current at the end of the test pulse is plotted against the test voltage for R421C (green) (n=19) and M485K (n=9) channels. WT data for cells in C is shown in grey.

Figure 3. Properties of simulated heterozygous mutant channels. (A) Representative current traces of WT channels and mutant channels that displayed no currents in homomeric condition. In simulated heterozygous condition these either showed currents with WT-like (A493Ehet) or shifted (P480Hhet) voltage dependence of activation. Inserts show a zoom to first 90 ms of the tail current to illustrate two distinct components of activation for P480Hhet channels. Scale bars: 250 ms (x), 3 µA (y). (B) Voltage dependence of activation of WT, A493Ehet and P480Hhet channels. The data were normalized as in 1B except for P480Hhet where tail currents in individual cells were normalized to peak amplitude of double Boltzmann equation. (C) Representative current traces of a variant with shifted voltage dependence of
activation in homomeric condition (S289G) co-expressed with WT subunits. Scale bars: 250 ms (x), 3 µA (y). (D) Voltage dependence of activation of WT (black), S289G (solid red) and S289Ghet (open red) channels. (E) $V_{1/2}$ of simulated heterozygous channels. Mean WT data±1.5SD cut-off voltage is shown in red, data in homomeric conditions with solid symbols and in simulated heterozygous conditions with open symbols. For variants with no, or reduced currents, in homomeric conditions only data in simulated heterozygous condition are shown. Variants with $V_{1/2}$ left of the cut-off voltage were considered recessive, while variants right of the cut-off voltage were considered dominant. Data for variants for which two component Boltzmann equation was used to describe the voltage dependence are not included. (F) Current amplitude of simulated heterozygous variants that in homomeric condition showed no or reduced currents and in heterozygous conditions showed WT-like voltage dependence. None of the variants suppressed current amplitude to below 50% of WT current amplitude, consistent with an absence of dominant negative effects on WT subunit function. (G) Voltage dependence of activation of L332Rhet (red) and P342Lhet (blue) channels using the $V_h$=-40 mV (solid symbols) or $V_{pp}$=-140 mV (open symbols) protocols. While the $V_{1/2}$ was WT-like using the $V_h$=-40 mV protocol, this was shifted when using the $V_{pp}$=-140 mV protocol ($V_{1/2}$(WT))= -4.4±0.4 mV, n=271, $V_{1/2}$(L332Rhet)= 27.0±4.1mV, n=8, $V_{1/2}$(P342L)= 28.4±4.9mV, n=6). (H) Voltage dependence of activation of R421Chet (green) and M485Khet (yellow) channels. (I) Voltage dependence of currents at the end of the test voltage pulse for R421Chet (green) and M485Khet (yellow) measured using the $V_{pp}$=-140 mV protocol. Data were normalized to peak tail current amplitude of the same cell measured using the standard protocol. The normalised current data indicates increased currents at hyperpolarized voltages for the simulated heterozygous mutant channels compared to WT channels.
Figure 4. Correlation of the functional properties with the inheritance pattern of clinical symptoms. Bar graph of inheritance patterns of all pedigrees for missense variants with WT-like, recessive and dominant functional features. Dominant inheritance pattern is indicated in red, sporadic inheritance in yellow and recessive inheritance in blue. Variants with uncertain association with clinical symptoms are shown in grey. Variants with unknown inheritance pattern are excluded from the Figure.

Figure 5. Alternative pathogenic mechanisms. (A) Representative current traces showing time course of activation of WT, A331S, F333L and L587V. Holding voltage was -80 mV, responses steps to voltages between -60 mV and +60 mV are shown. (A, D) Scale bars: 50 ms (x), 5 µA (y). (B, C). Time constant (B) and voltage dependence (C) of activation for WT (black), A331S (blue) and F333L (orange) channel. Solid symbols show data for $V_{h}=-40$ mV protocol, open symbols for $V_{PP}=-140$ mV protocol. (D) Representative current traces showing time course of deactivation of WT and L587V channels. Holding voltage was -80 mV, traces show the time course of closure following pre-pulse to +60 mV for voltage range +50 mV to -150 mV. (E, F). Time constants of activation and deactivation (E) and voltage dependence of activation (F) for WT (black) and L587V (pink) channels. Solid symbols show data for $V_{h}=-40$ mV protocol, open symbols for $V_{PP}=-140$ mV protocol.

Figure 6. Mapping of substituted residues (variants) to CIC-1 structure. (A) Two-dimensional map of variants. Top: CIC-1 intramembrane helices are represented as squares, CBS domains as ovals and the connecting loops as lines. Blue indicates TM1, pink TM2, black intracellular (IC). Helices B, I, J and R are indicated. Below: Location of all the variants in this cohort is shown on top row and location of the variants with distinct functional features is specified below. Two rows of recessive variants are shown depending on if the variant in homomeric condition shifted voltage dependence (Recessive (shift)) or just reduced functional expression (Recessive (no shift)). Outliers include the variants shown in figures 2 and 5. (B)
Percentage of variants located in intracellular domains (grey), TM1 (blue) or TM2 (pink) is plotted for variants with distinct functional features. (C) Percentage of variants with dominant (yellow), recessive (shift) (orange) or recessive (no shift) (red) and WT-like functional features (blue) is plotted for variants located in the intracellular domains (IC), TM1 or TM2. (D) Mapping variants to TM1s (left, light blue) and TM2 (right, light pink) to ClC-1 structure (6COY). 22 TMs of both subunits are shown, variants are plotted on both subunits, Cl⁻ are shown in black. View is on membrane plane. Cl⁻ ions (black) on left and right graphs are aligned to illustrate location of TM2 higher up in membrane plane compared to TM1. Top row shows dominant variants in yellow and Recessive (shift) in orange. Bottom row shows Recessive (no shift) variants in red. Variants with WT-like functional features are shown in blue. (E) Top row shows a view from above membrane plane with the two TM1s (left, light blue) or TM2s (right, light pink) shown in cartoon while the other TM is shown in ribbon. On bottom row all variants are mapped based on their functional group as in B. Most of subunit interface is formed by the two TM1s (top) and most variants that shift voltage dependence of activation at any condition are located here. (F) Variants with attenuated activation particularly following hyperpolarized pre-pulse (L332 and P342 in red, A331 and F333 in orange) are shown viewed from above the membrane plane. These variants are located on IJ-linker (main chain is shown in light green spheres) that forms interface with IJ-linker of neighbouring subunit and reaches to proximity of variants that showed enhanced currents at hyperpolarized voltage (R421C (magenta) and M485K (cyan)). (G) Location of L587V (green) variant that accelerated both opening and closing of the channel at the intracellular opening of the selectivity filter pathway. The F297S (orange) variant that displayed larger shift in voltage dependence of activation when co-expressed with WT subunits compared to homomeric F297S channels is also shown. Note that the variants mentioned in F or the L587V variant are not shown in B or C.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
| Variant | Functional | Dominant | Sporadic | Clinical / Genetic | Uncertain | Unknown | Sum | Location |
|---------|------------|----------|----------|---------------------|-----------|---------|-----|----------|
| p.His29Pro | WT-like    | -        | -        | 1                   | -         | -       | 1   | IC       |
| p.Ser70Leu | WT-like    | -        | -        | 1                   | -         | -       | 1   | IC       |
| p.Arg105Cys | WT-like    | -        | -        | 1                   | -         | -       | 1   | IC       |
| p.Leu106Val* | WT-like    | -        | -        | 1                   | -         | -       | 1   | IC       |
| p.Gln154Arg | WT-like    | -        | -        | 1                   | -         | -       | 1   | TM1      |
| p.Gly222Ser | WT-like    | -        | -        | 1                   | -         | -       | 1   | TM1      |
| p.Val327Ile | WT-like    | -        | -        | -                   | 2         | 2       | 4   | TM2      |
| p.Ala402Val | WT-like    | -        | -        | 1                   | -         | -       | 1   | TM2      |
| p.Pro429Ala | WT-like    | -        | -        | 2                   | 3         | 6       | 11  | TM2      |
| p.Val458Le* | WT-like    | -        | -        | -                   | 1         | 1       | 2   | TM2      |
| p.Ala493Thr* | WT-like    | -        | -        | -                   | 1         | 1       | 2   | TM2      |
| p.Gly594Val* | WT-like    | -        | -        | -                   | 1         | 1       | 2   | IC       |
| p.Arg611His* | WT-like    | -        | -        | 1                   | -         | -       | 2   | IC       |
| p.Met646Thr* | WT-like    | -        | -        | 1                   | -         | -       | 2   | IC       |
| p.Arg669Cys | WT-like    | -        | -        | 1                   | -         | -       | 2   | IC       |
| p.Gly688Arg* | WT-like    | -        | -        | -                   | 1         | 1       | 2   | TM1      |
| p.Pro744Thr* | WT-like    | -        | -        | 1                   | -         | -       | 2   | TM1      |
| p.Trp837Ile* | WT-like    | -        | -        | 1                   | -         | -       | 2   | TM2      |
| p.Val851Met | WT-like    | -        | -        | 2                   | -         | -       | 2   | IC       |
| p.Gly898Arg* | WT-like    | -        | -        | 1                   | -         | -       | 2   | IC       |
| Total     | WT-like    | -        | 2        | 12                  | 11        | 10      | 35  |          |
| p.Phe167Leu | Recessive* | -        | -        | 7                   | 4         | 2       | 13  | TM1      |
| p.Gly190Arg | Recessive* | -        | -        | 3                   | 1         | -       | 4   | TM1      |
| p.Leu198Val | Recessive* | -        | -        | -                   | 1         | -       | 1   | TM1      |
| p.Ala221Glu* | Recessive* | -        | -        | 1                   | -         | -       | 1   | TM1      |
| p.Gly225Ser | Recessive* | -        | -        | 1                   | -         | -       | 1   | TM1      |
| p.Val327Ile | Recessive* | -        | -        | 1                   | -         | -       | 1   | TM1      |
| p.Val327Ile | Recessive* | -        | -        | 1                   | -         | -       | 1   | TM1      |
| p.Ala529Val | Recessive* | -        | -        | 1                   | -         | -       | 1   | TM1      |
| p.Gly556Val | Recessive* | -        | -        | -                   | 1         | 1       | 2   | TM2      |
| p.Glu585Val | Recessive* | -        | -        | 1                   | -         | -       | 1   | TM2      |
| p.Glu585Val | Recessive* | -        | -        | 1                   | -         | -       | 1   | TM2      |
| p.Glu585Val | Recessive* | -        | -        | -                   | 1         | 1       | 2   | TM2      |
| p.Arg611His* | Recessive* | -        | -        | -                   | 1         | 1       | 2   | IC       |
| p.Glu629Ser | Recessive* | -        | -        | -                   | 1         | 1       | 2   | IC       |
| p.Glu629Ser | Recessive* | -        | -        | -                   | 1         | 1       | 2   | IC       |
| p.Glu629Ser | Recessive* | -        | -        | -                   | 1         | 1       | 2   | IC       |
| Total     | Recessive* | -        | 1        | 7                   | 4         | 2       | 13  | TM1      |
| p.Leu587Val | Recessive* | -        | -        | 2                   | -         | -       | 2   | IC       |
| p.Pro695Ser | Recessive* | -        | -        | 1                   | -         | -       | 2   | IC       |
| p.Arg708Cys | Recessive* | -        | -        | -                   | 1         | 1       | 2   | TM2      |
| p.Glu727Ser | Recessive* | -        | -        | -                   | 1         | 1       | 2   | TM2      |
| p.Pro744Thr | Recessive* | -        | -        | -                   | 1         | 1       | 2   | TM2      |
| p.Pro744Thr | Recessive* | -        | -        | -                   | 1         | 1       | 2   | TM2      |
| p.Pro744Thr | Recessive* | -        | -        | -                   | 1         | 1       | 2   | TM2      |
| Total     | Recessive* | -        | 1        | 7                   | 4         | 2       | 13  | TM1      |
| p.His138Pro | Recessive* | -        | -        | 1                   | -         | -       | 1   | TM2      |
| p.Val140Met | Recessive* | -        | -        | 1                   | -         | -       | 1   | TM2      |
| p.Arg192Cys | Recessive* | -        | -        | -                   | 1         | 1       | 2   | TM2      |
| p.Glu200Val | Recessive* | -        | -        | 1                   | -         | -       | 1   | TM2      |
| p.Arg206Ala | Recessive* | -        | -        | 1                   | -         | -       | 1   | TM2      |
| p.Arg206Ala | Recessive* | -        | -        | 1                   | -         | -       | 1   | TM2      |
| p.Arg206Ala | Recessive* | -        | -        | 1                   | -         | -       | 1   | TM2      |
| Total     | Recessive* | -        | 1        | 7                   | 4         | 2       | 13  | TM1      |
| Variant      | Classification | Functional | Location | Clinical/Genetic | Location |
|--------------|----------------|------------|----------|-----------------|----------|
| p.Thr550Met  | Recessive      | -          | -        | -               | TM2      |
| p.Pro558Ser  | Recessive      | -          | -        | 2               | TM2      |
| p.Met560Thr  | Recessive      | -          | -        | 1               | TM2      |
| p.Ala566Thr  | Recessive      | -          | -        | 2               | TM2      |
| p.Gln583Arg* | Recessive      | -          | -        | 1               | TM2      |
| p.Val640Phe* | Recessive      | -          | -        | 1               | IC       |
| p.Asp822Asn* | Recessive      | -          | -        | 1               | IC       |
| p.Pro883Thr  | Recessive      | -          | -        | 2               | IC       |
| **Total**    | Recessive      | 1          | -        | 38              | 12       |

Asterisks following variant name indicate variants not reported in the literature previously. Functional = classification according to functional feature; Clinical/Genetic = number of pedigrees with distinct inheritance patterns of clinical symptoms. Location = if the variant is found in intracellular domain (IC: residues 1–110, 586–988), first (TM1: residues 111–344) or second (TM2: residues 345–585) of the transmembrane repeats. Data for the variants that were not missense are presented in Supplementary Table 3.

For recessive variants it is specified if the variant in homomeric condition expresses currents with shifted voltage dependence of activation or reduced current amplitude.
| Variant          | Functional | Clinical / Genetic | Sum | Location |
|------------------|------------|--------------------|-----|----------|
| p.Met128Ile      | Dominant   | 2                  | 2   | TM1      |
| p.Cys179Tyr*     | Dominant   | 1                  | 1   | TM1      |
| p.Ser183Pro      | Dominant   | 1                  | 1   | TM1      |
| p.Gly190Ser      | Dominant   | -                  | 3   | TM1      |
| p.Leu200Pro      | Dominant   | -                  | 1   | TM1      |
| p.Gly200Glu*     | Dominant   | -                  | 1   | TM1      |
| p.Ala218Val      | Dominant   | 1                  | 1   | TM1      |
| p.Gly230Glu      | Dominant   | 29                 | 5   | TM1      |
| p.Pro234Thr*     | Dominant   | -                  | 1   | TM1      |
| p.Pro234Leu*     | Dominant   | -                  | 1   | TM1      |
| p.Thr268Met      | Dominant   | 1                  | 2   | TM1      |
| p.Cys271Arg      | Dominant   | 1                  | 2   | TM1      |
| p.Gly276Asp      | Dominant   | 2                  | -   | TM1      |
| p.Gly285Glu      | Dominant   | 5                  | 9   | TM1      |
| p.Ser289Asn      | Dominant   | 1                  | 1   | TM1      |
| p.Ser289Gly*     | Dominant   | 1                  | -   | TM1      |
| p.Val299Leu      | Dominant   | -                  | 2   | TM1      |
| p.Trp303Arg      | Dominant   | 12                 | 2   | TM1      |
| p.Phe306Leu      | Dominant   | 2                  | 1   | TM1      |
| p.Phe307Ser*     | Dominant   | 1                  | 2   | TM1      |
| p.Ala313Thr      | Dominant   | 9                  | 1   | TM1      |
| p.Ala313Val      | Dominant   | 2                  | -   | TM1      |
| p.Val321Leu      | Dominant   | -                  | 4   | TM1      |
| p.Thr328Ile      | Dominant   | 1                  | -   | TM1      |
| p.His328Leu      | Dominant   | -                  | 2   | TM1      |
| p.Pro480His      | Dominant   | -                  | -   | TM1      |
| p.Phe480Ser      | Dominant   | -                  | -   | TM1      |
| p.Gly523Asp      | Dominant   | -                  | -   | TM1      |
| p.Val536Asp      | Dominant   | -                  | -   | TM1      |
| p.Gly551Asp      | Dominant   | -                  | -   | TM1      |
| Total            | Dominant   | 80                 | 17  | TM1      |
| p.Leu332Arg*     | Other      | -                  | 1   | TM1      |
| p.Pro342Leu*     | Other      | -                  | 1   | TM1      |
| p.Arg421Cys      | Other      | -                  | 1   | TM1      |
| p.Met485Lys*     | Other      | -                  | 1   | TM1      |
| Total            | All        | 81                 | 21  | TM1      |

Asterisks following variant name indicate variants not reported in the literature previously. Functional = classification according to functional feature; Clinical/Genetic = number of pedigrees with distinct inheritance patterns of clinical symptoms. Location = if the variant is found in intracellular domain (IC: residues 1–110, 586–988), first (TM1: residues 111–344) or second (TM2: residues 345–585) of the transmembrane repeats. ‘Other’ indicates that the functional features could not be classified as WT-like, dominant or recessive. Data on row ‘All’ includes data from Tables 1 and 2.